News >

Published Data Demonstrate Avelumab Activity in Platinum-Refractory Bladder Cancer

Jason Harris
Published: Thursday, Jan 18, 2018

Andrea Apolo, MD
Andrea Apolo, MD
The PD-L1 inhibitor avelumab (Bavencio) induced an overall response rate of 17% in patients with platinum-refractory metastatic urothelial carcinoma, according to results from the phase I JAVELIN Solid Tumor study now published in the Lancet Oncology.

The ongoing phase III JAVELIN Bladder 100 trial (NCT02603432) is examining avelumab as a maintenance therapy in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line platinum-containing chemotherapy.
Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial [published online December 7, 2017]. Lancet Oncol. 2018;19(1):51-64. doi: 10.1016/S1470-2045(17)30900-2.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x